| Bradley Pharmaceuticals, Inc. | |
|---|---|
 |
|
| Type | Public (NYSE: BDY) |
| Founded | 1985 |
| Headquarters | Fairfield Township, Essex County, New Jersey |
| Key people | Daniel Glassman (CEO) |
| Industry | Pharmaceuticals |
| Products | Adoxa, Zoderm, Pamine Forte, Kerol |
| Revenue | US$145 million (2006) |
| Employees | 300 (as of December 31, 2006) |
| Website | www.bradpharm.com |
Bradley Pharmaceuticals is a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey. The company was founded in 1985 by Daniel Glassman who is at the current time its CEO. The company markets to niche physician specialties in the U.S. and 38 international markets. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Doak Dermatologics
Doak Dermatologics is the division of Bradley Pharmaceuticals that markets products to dermatologist. Its flag products are Zoderm which is a topical anti-acne product. Adoxa (doxycycline) is an antibiotic intended to treat mild to severe acne.
Kenwood Therapeutics
Kenwood is the affiliate brand that works with therapeutic products. Among the most prescribed ones are Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.
Public trading
The company is publicly traded at the NYSE by its code BDY since May 2003.
